| pubmed-article:18208763 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18208763 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:18208763 | lifeskim:mentions | umls-concept:C0021311 | lld:lifeskim |
| pubmed-article:18208763 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18208763 | lifeskim:mentions | umls-concept:C0301872 | lld:lifeskim |
| pubmed-article:18208763 | lifeskim:mentions | umls-concept:C1522405 | lld:lifeskim |
| pubmed-article:18208763 | lifeskim:mentions | umls-concept:C0887947 | lld:lifeskim |
| pubmed-article:18208763 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:18208763 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18208763 | pubmed:dateCreated | 2008-1-22 | lld:pubmed |
| pubmed-article:18208763 | pubmed:abstractText | The efficacy of recombinant interleukin-2 (rIL-2) was assessed in HIV-infected patients with advanced immune suppression and a discordant immune response to highly active antiretroviral therapy (HAART). The primary endpoint was median change in CD4+ T-cell counts at the end of treatment as compared to baseline. Secondary endpoints were safety and changes in the various T-cell subpopulations. | lld:pubmed |
| pubmed-article:18208763 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18208763 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18208763 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18208763 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18208763 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18208763 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18208763 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18208763 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18208763 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18208763 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:18208763 | pubmed:issn | 0213-005X | lld:pubmed |
| pubmed-article:18208763 | pubmed:author | pubmed-author:PahissaAlbert... | lld:pubmed |
| pubmed-article:18208763 | pubmed:author | pubmed-author:RiberaEsteban... | lld:pubmed |
| pubmed-article:18208763 | pubmed:author | pubmed-author:CrespoManuelM | lld:pubmed |
| pubmed-article:18208763 | pubmed:author | pubmed-author:CaragolIsabel... | lld:pubmed |
| pubmed-article:18208763 | pubmed:author | pubmed-author:FalcóVicençV | lld:pubmed |
| pubmed-article:18208763 | pubmed:author | pubmed-author:UrbanSusanaS | lld:pubmed |
| pubmed-article:18208763 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18208763 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:18208763 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18208763 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18208763 | pubmed:pagination | 27-31 | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:meshHeading | pubmed-meshheading:18208763... | lld:pubmed |
| pubmed-article:18208763 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18208763 | pubmed:articleTitle | Efficacy of recombinant interleukin-2 (rIL-2) in patients with advanced HIV-1 infection and blunted immune response to HAART. | lld:pubmed |
| pubmed-article:18208763 | pubmed:affiliation | Infectious Diseases Department, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain. mcrespo@vhebron.net | lld:pubmed |
| pubmed-article:18208763 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18208763 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18208763 | lld:pubmed |
